May 28, 2010

May 28, 2011

1.0 Hours

Internet

This Virtual Poster Hall program features a lively discussion between two rotavirus experts about safety, efficacy, and impact of the two currently licensed rotavirus vaccines. Topics covered include an overview of how the universal vaccination program for rotavirus is changing the epidemiology of the disease in the United States. The program also provides a more detailed look at vaccine efficacy and safety both in clinical trials and in real-world settings along with a discussion of when it is and is not appropriate to vaccinate infants. The activity also includes frequently asked questions concerning comparisons of the two approved rotavirus vaccines, including information on serotypes and what is known to date about partial vaccination.

This activity has been designed to meet the educational needs of pediatricians, infectious disease specialists, and primary care physicians, along with allied healthcare workers that treat children.

• Identify whether an infant presenting at your practice is an appropriate candidate for rotavirus vaccine by knowing the contraindications and precautions to vaccination, including the recently added contraindications to vaccination.
• Establish the impact of the rotavirus vaccines to date. Describe how the vaccination programs have affected seasonality in the US and how this has translated into real-world emergency room and hospitalization rate decreases.
• Describe the appropriate steps to take if a 4-month old child has received one previous rotavirus vaccination, but the product used is unknown.

Penelope H. Dennehy, MD
Professor and Vice Chair of Pediatrics
The Alpert Medical School of Brown University
Rhode Island Hospital
Director, Pediatric Infectious Diseases
Hasbro Children's Hospital
Providence, Rhode Island

Stephen I. Pelton, MD
Professor of Pediatrics and Epidemiology
Boston University School of Medicine and Public Health
Chief, Section of Pediatric Infectious Diseases
Boston, Medical Center
Boston, Massachusetts

Mary Beth Koslap-Petraco, DNP, CPNP
Course Director
Clinical Assistant Professor
School of Nursing
Stony Brook University School of Nursing
Coordinator-Child Health
Patient Care Division
Suffolk County Department of Health Services
Hauppauge, New York

Katherin Galluzzi, DO, CMD, FACOFP dist.
Course Reviewer
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Attending Physician
Roxborough Memorial Hospital
Philadelphia, Pennsylvania

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: medlearninggroup.com/Privacy.aspx

Copyright: © 2010 Med Learning Group

Med Learning Group designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)^TM. Physicians should only claim commensurate with the extent of their participation in the activity.

There are no fees for participating and receiving CME credit for this activity. During the period May 28, 2010 through May 28, 2011, participants must:

1. Read the educational objectives and faculty disclosures
2. Study all parts of the educational avtivity
3. Complete the posttest by recording the best answer to each question in the answer key and submit the evaluation form.
4. Submit the evaluation form online via iQueue.

To participate in this activity, please view the presentation and take the posttest. Fill in the answer sheet and evaluation form and submit online Via iQueue. CME credit will be awarded if a score of 70% or better is achieved. You will recieve your certificate instantly.

Med Learning Group requires all individuals involved in the development and presentation of continuing medical education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Med Learning Group has procedures to resolve apparent conflicts of interest. Faculty members are also requested to disclose when unapproved use of pharmaceuticals and devices are being discussed.

Penelope H. Dennehy, MD
Professor and Vice Chair of Pediatrics
The Alpert Medical School of Brown University
Rhode Island Hospital
Director, Pediatric Infectious Diseases
Hasbro Children's Hospital
Providence, Rhode Island

Disclosure: Penelop H. Dennehy, MD:
Contracted Research: Med Immune Inc., Merck & Co.,Inc., and Roche

Stephen I. Pelton, MD
Professor of Pediatrics and Epidemiology
Boston University School of Medicine and Public Health
Chief, Section of Pediatric Infectious Diseases
Boston Medical Center
Boston, Massachusetts

Disclosure: Stephen I. Pelton, MD
Grant/Research Support: GlaxoSmithKline, Novartis Pharmaceuticals, and Wyeth Pharmaceuticals
Consultant: GlaxoSmithKline, Novartis Pharmaceutical, and Wyeth Pharmaceuticals

Mary Beth Koslap-Petraco, DNP, CPNP
Course Director
Clinical Assistant Professor
School of Nursing
Stony Brook University School of Nursing
Coordinator-Child Health
Patient Care Division
Suffolk County Department of Health Services
Hauppauge, New York

Disclosure: Mary Beth Koslap-Petraco, DNP, CPNP
Speakers' Bureaus: GlaxoSmithKline, Med Immune, Inc., Merck & Co., Inc., and sanofi pasteur

Katherine Galluzzi, DO, CMD, FACOFP dist.
Course Reviewer
Professor and Chairperson
Department of Geriatrics
Philadelphia College of Osteopathic Medicine
Attending Physician
Roxborough Memorial Hospital
Philadelphia, Pennsylvania

Disclosure: Katherine Galluzzi, DO, CMD, FACOFP dist.
Advisory Board: Pfizer

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Tara Hun-Dorris, MMC, ELS, of THD Editorial, Inc., has nothing to disclose.

Christopher Cahill of Med Learning Group has nothing to disclose..

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes.

On March 23, 2010, the rotavirus vaccine RV1 was found to contain DNA material from porcine circovirus type 1 (PCV1). On May 6, 2010, the FDA indicated that preliminary studies conducted by the drug maker of RV5 identified fragments of DNA from PCV1 and from a related porcine circovirus type 2 (PCV2).

The FDA has determined it is appropriate for clinicians and healthcare professionals to continue use of both RV1 and RV5 vaccines. The FDA also recommends that clinicians and public health professionals inform parents of the findings of PCV DNA or PCV in rotavirus vaccines, and that there is no evidence that these findings pose a safety risk in humans. Both the prescribing information and patient labeling will be revised to include this information.

The benefits of vaccination against rotavrius desease are substantial, both in the United States and the developing world and far outweigh any theoretical risk posed by PCV types 1 and 2. The safety record of both rotavirus vaccines is excellent.

iQueue is accessible using the Adobe AIR software. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, or Microsoft PowerPoint.